Univercells and Altamira Therapeutics have joined forces to work on nanoparticle-delivered mRNA vaccines Univercells has recently partnered with Altamira Therapeutics, a leading producer of nanoparticle-based technology. This collaboration will allow Univercells to utilize Altamira's innovative SemaPhore nanoparticle platform for the delivery of messenger RNA (mRNA) vaccines. Additionally, on
Developed by J&J, nipocalimab reduces the risk of FNAIT in alloimmunized pregnant individuals On March 26, 2024, Johnson & Johnson (J&J) shared that the FDA has given fast track designation to nipocalimab. This is an investigational monoclonal antibody (mAb) that aims to reduce the risk of
AbbVie's acquisition of Landos contains a lead asset that expands its portfolio in autoimmune and inflammatory illnesses. On March 25, 2024, AbbVie made a definitive agreement to acquire Landos, a clinical-stage biopharmaceutical company that specializes in autoimmune diseases. This acquisition comes after the recent news of FDA'
Lonza has acquired a significant biologics manufacturing site for mammalian cell-based therapeutics On March 20, 2024, Lonza revealed its plans to acquire Roche's Vacaville, Calif., site. This site is known for its large-scale biologics manufacturing and the acquisition is valued at $1.2 billion. In addition to the
Optima Partners' health data science division, bioXcelerate, has recently unveiled a new tool designed to expedite the drug discovery process. In a press release dated March 20, 2024, the e health data science division of Optima Partners Limited, bioXcelerate, unveiled PleioGraph, an innovative artificial intelligence (AI) tool. PleioGraph aims
Lenmeldy from Orchard Therapeutics has become the inaugural gene therapy to receive approval in the United States for the treatment of metachromatic leukodystrophy in children. Orchard Therapeutics received FDA approval on March 18, 2024 for Lenmeldy (atidarsagene autotemcel), making it the first gene therapy approved by the FDA to treat
The FDA has recently released a draft guidance to assist sponsors in the development of treatments for sporadic Alzheimer's disease. On March 12, 2024, the FDA released a preliminary guide for creating treatments for early-stage Alzheimer's disease (AD). This guidance document is designed to help sponsors
The company is making a significant investment of over $2 million to enhance its analytical testing services and expand its manufacturing capabilities to include suppositories. LGM Pharma, a contract development and manufacturing organization (CDMO), recently shared exciting news. On March 13, 2024, they announced a significant investment of over $2
The North American branch of the Italian company has experienced a 47% growth. Bormioli Pharma, a global manufacturer of pharmaceutical packaging and medical devices located in Milan, Italy, revealed on March 12, 2024 that the company experienced a 47% growth in North American sales for 2023. The company attributes the
AbbVie and OSE Immunotherapeutics have partnered under a global license on developing OSE-230, a mAb designed to treat chronic inflammation. AbbVie and OSE Immunotherapeutics, a clinical-stage immunotherapy company, revealed on February 28, 2024 that they are collaborating to work on OSE-230, a monoclonal antibody (mAb) aimed at addressing chronic and
This collaboration will enable both companies to offer comprehensive biopharmaceutical manufacturing solutions. BioCina, a biologics contract development and manufacturing organization (CDMO) and NovaCina, a global fill-and-finish CDMO, have joined forces to provide integrated drug substance and drug product solutions for biologics developers. This will enable BioCina to offer fill/finish
CordenPharma has introduced new starter kits to facilitate formulation in the creation of mRNA-based therapeutics CordenPharma International's promotes the latest Lipid NanoParticle (LNP) Starter Kits. These kits are designed for creating messenger RNA (mRNA)-based therapeutics like mRNA vaccines or gene therapies. The starter kits are created to